Clinical experiment designed to assess clinical efficacy targeting MA in human. Primary outcome: Correlation coefficient between CSF autophagy flux markers (LC3-II/I ratio, p62 levels) and alpha-sy
Description
Macroautophagy Dysfunction in PD - Experiment Design
Background and Rationale
This clinical study investigates the central hypothesis that macroautophagy dysfunction serves as an upstream pathogenic driver of alpha-synuclein aggregation in Parkinson's disease. The research addresses the critical knowledge gap regarding the temporal relationship between autophagy impairment and protein misfolding in neurodegeneration. Using a comprehensive biomarker approach, the study will examine autophagy flux markers (LC3-II/I ratio, p62/SQSTM1 levels, Beclin-1 expression) in cerebrospinal fluid and peripheral blood samples from PD patients across disease stages, correlating these with alpha-synuclein seed amplification assay (SAA) positivity and clinical progression metrics. The experimental design incorporates longitudinal sampling to establish whether autophagy dysfunction precedes or follows alpha-synuclein pathology, with parallel analysis of genetic variants in autophagy-related genes (ATG5, ATG7, LRRK2) that may predispose to macroautophagy impairment....
Macroautophagy Dysfunction in PD - Experiment Design
Background and Rationale
This clinical study investigates the central hypothesis that macroautophagy dysfunction serves as an upstream pathogenic driver of alpha-synuclein aggregation in Parkinson's disease. The research addresses the critical knowledge gap regarding the temporal relationship between autophagy impairment and protein misfolding in neurodegeneration. Using a comprehensive biomarker approach, the study will examine autophagy flux markers (LC3-II/I ratio, p62/SQSTM1 levels, Beclin-1 expression) in cerebrospinal fluid and peripheral blood samples from PD patients across disease stages, correlating these with alpha-synuclein seed amplification assay (SAA) positivity and clinical progression metrics. The experimental design incorporates longitudinal sampling to establish whether autophagy dysfunction precedes or follows alpha-synuclein pathology, with parallel analysis of genetic variants in autophagy-related genes (ATG5, ATG7, LRRK2) that may predispose to macroautophagy impairment. This study has significant translational potential, as establishing macroautophagy as an upstream driver could identify novel therapeutic targets and biomarkers for early intervention in PD, potentially before irreversible neuronal loss occurs.
This experiment directly tests predictions arising from the following hypotheses:
Transcriptional Autophagy-Lysosome Coupling
Circadian-Synchronized Proteostasis Enhancement
Autophagosome Maturation Checkpoint Control
Circadian Clock-Autophagy Synchronization
VCP-Mediated Autophagy Enhancement
Experimental Protocol
Phase 1 (Months 1-18): Generate iPSCs from 30 PD patients and 20 healthy controls, differentiate into midbrain dopaminergic neurons using established protocols. At days 35, 50, 65 post-differentiation, assess autophagy flux using bafilomycin A1 treatment (100nM, 4h) followed by LC3-II Western blot and immunofluorescence. Measure p62 accumulation, LAMP1 expression, and cathepsin B/D activity using fluorogenic substrates. Quantify alpha-synuclein aggregation via filter trap assay and Thioflavin-T staining. Assess neuronal viability using MTT assay and caspase-3 activation. Perform rescue experiments using autophagy modulators (rapamycin 100nM, trehalose 100mM). Phase 2 (Months 12-24): Recruit 100 PD patients (Hoehn-Yahr stages 1-3) and 50 age-matched controls. Collect cerebrospinal fluid and plasma samples. Measure ATG5, ATG7, Beclin-1, LC3, p62 levels via ELISA. Assess lysosomal enzymes (β-glucocerebrosidase, α-galactosidase) and alpha-synuclein species (monomeric, oligomeric, phosphorylated) using established immunoassays. Correlate biomarker levels with clinical severity (UPDRS-III, MoCA scores). Statistical analysis using linear mixed-effects models for longitudinal cellular data and multivariate regression for clinical correlations. Power analysis indicates n=80 patients needed to detect 30% biomarker differences with 80% power, α=0.05.
Expected Outcomes
PD patient-derived neurons will show 40-60% reduced autophagy flux compared to controls, evidenced by decreased LC3-II/LC3-I ratios and increased p62 accumulation (p<0.01)
Autophagy dysfunction will precede alpha-synuclein aggregation by 10-15 days in longitudinal tracking, with 2-3 fold increase in Thioflavin-T positive aggregates following autophagy impairment
Cerebrospinal fluid from PD patients will demonstrate 25-40% decreased ATG protein levels and 50-70% reduced lysosomal enzyme activity compared to healthy controls (p<0.001)
Plasma biomarkers will show moderate correlation with disease severity (r=0.4-0.6, p<0.01) and distinguish early-stage PD from controls with 75-85% sensitivity and specificity
Autophagy rescue interventions will reduce alpha-synuclein aggregation by 50-70% and improve neuronal viability by 30-50% in cellular models
Strong inverse correlation (r=-0.6 to -0.8) between autophagy biomarkers and alpha-synuclein pathological species across both cellular and clinical cohorts
Success Criteria
• Demonstrate statistically significant autophagy dysfunction in ≥70% of PD patient-derived neuronal cultures compared to controls (p<0.01)
• Establish temporal precedence of autophagy impairment over alpha-synuclein aggregation with ≥10-day lead time in longitudinal studies
• Identify ≥3 cerebrospinal fluid biomarkers showing ≥30% difference between PD patients and controls with area under curve ≥0.75
• Achieve successful autophagy rescue resulting in ≥50% reduction in alpha-synuclein pathology in cellular models using 2 independent interventions
• Demonstrate significant correlation (r≥0.4, p<0.05) between autophagy biomarkers and clinical disease severity measures in ≥80 patients
• Validate findings in independent replication cohort of ≥30 patients showing consistent directional effects with effect size ≥0.5
TARGET GENE
MA
MODEL SYSTEM
human
ESTIMATED COST
$5,460,000
TIMELINE
45 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Correlation coefficient between CSF autophagy flux markers (LC3-II/I ratio, p62 levels) and alpha-synuclein SAA positivity in PD patients compared to healthy controls, measured at baseline and 12-month follow-up.
Phase 1 (Months 1-18): Generate iPSCs from 30 PD patients and 20 healthy controls, differentiate into midbrain dopaminergic neurons using established protocols. At days 35, 50, 65 post-differentiation, assess autophagy flux using bafilomycin A1 treatment (100nM, 4h) followed by LC3-II Western blot and immunofluorescence. Measure p62 accumulation, LAMP1 expression, and cathepsin B/D activity using fluorogenic substrates. Quantify alpha-synuclein aggregation via filter trap assay and Thioflavin-T staining. Assess neuronal viability using MTT assay and caspase-3 activation. Perform rescue experiments using autophagy modulators (rapamycin 100nM, trehalose 100mM). Phase 2 (Months 12-24): Recruit 100 PD patients (Hoehn-Yahr stages 1-3) and 50 age-matched controls.
...
Phase 1 (Months 1-18): Generate iPSCs from 30 PD patients and 20 healthy controls, differentiate into midbrain dopaminergic neurons using established protocols. At days 35, 50, 65 post-differentiation, assess autophagy flux using bafilomycin A1 treatment (100nM, 4h) followed by LC3-II Western blot and immunofluorescence. Measure p62 accumulation, LAMP1 expression, and cathepsin B/D activity using fluorogenic substrates. Quantify alpha-synuclein aggregation via filter trap assay and Thioflavin-T staining. Assess neuronal viability using MTT assay and caspase-3 activation. Perform rescue experiments using autophagy modulators (rapamycin 100nM, trehalose 100mM). Phase 2 (Months 12-24): Recruit 100 PD patients (Hoehn-Yahr stages 1-3) and 50 age-matched controls. Collect cerebrospinal fluid and plasma samples. Measure ATG5, ATG7, Beclin-1, LC3, p62 levels via ELISA. Assess lysosomal enzymes (β-glucocerebrosidase, α-galactosidase) and alpha-synuclein species (monomeric, oligomeric, phosphorylated) using established immunoassays. Correlate biomarker levels with clinical severity (UPDRS-III, MoCA scores). Statistical analysis using linear mixed-effects models for longitudinal cellular data and multivariate regression for clinical correlations. Power analysis indicates n=80 patients needed to detect 30% biomarker differences with 80% power, α=0.05.
Expected Outcomes
PD patient-derived neurons will show 40-60% reduced autophagy flux compared to controls, evidenced by decreased LC3-II/LC3-I ratios and increased p62 accumulation (p<0.01)
Autophagy dysfunction will precede alpha-synuclein aggregation by 10-15 days in longitudinal tracking, with 2-3 fold increase in Thioflavin-T positive aggregates following autophagy impairment
Cerebrospinal fluid from PD patients will demonstrate 25-40% decreased ATG protein levels and 50-70% reduced lysosomal enzyme activity compared to healthy controls (p<0.001)
Plasma biomarkers will show moderate correlation with
...
PD patient-derived neurons will show 40-60% reduced autophagy flux compared to controls, evidenced by decreased LC3-II/LC3-I ratios and increased p62 accumulation (p<0.01)
Autophagy dysfunction will precede alpha-synuclein aggregation by 10-15 days in longitudinal tracking, with 2-3 fold increase in Thioflavin-T positive aggregates following autophagy impairment
Cerebrospinal fluid from PD patients will demonstrate 25-40% decreased ATG protein levels and 50-70% reduced lysosomal enzyme activity compared to healthy controls (p<0.001)
Plasma biomarkers will show moderate correlation with disease severity (r=0.4-0.6, p<0.01) and distinguish early-stage PD from controls with 75-85% sensitivity and specificity
Autophagy rescue interventions will reduce alpha-synuclein aggregation by 50-70% and improve neuronal viability by 30-50% in cellular models
Strong inverse correlation (r=-0.6 to -0.8) between autophagy biomarkers and alpha-synuclein pathological species across both cellular and clinical cohorts
Success Criteria
• Demonstrate statistically significant autophagy dysfunction in ≥70% of PD patient-derived neuronal cultures compared to controls (p<0.01)
• Establish temporal precedence of autophagy impairment over alpha-synuclein aggregation with ≥10-day lead time in longitudinal studies
• Identify ≥3 cerebrospinal fluid biomarkers showing ≥30% difference between PD patients and controls with area under curve ≥0.75
• Achieve successful autophagy rescue resulting in ≥50% reduction in alpha-synuclein pathology in cellular models using 2 independent interventions
• Demonstrate significant correlation
...
• Demonstrate statistically significant autophagy dysfunction in ≥70% of PD patient-derived neuronal cultures compared to controls (p<0.01)
• Establish temporal precedence of autophagy impairment over alpha-synuclein aggregation with ≥10-day lead time in longitudinal studies
• Identify ≥3 cerebrospinal fluid biomarkers showing ≥30% difference between PD patients and controls with area under curve ≥0.75
• Achieve successful autophagy rescue resulting in ≥50% reduction in alpha-synuclein pathology in cellular models using 2 independent interventions
• Demonstrate significant correlation (r≥0.4, p<0.05) between autophagy biomarkers and clinical disease severity measures in ≥80 patients
• Validate findings in independent replication cohort of ≥30 patients showing consistent directional effects with effect size ≥0.5